Global Neuroendocrine Tumours Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Veröffentlicht von: Precision business insights
Veröffentlicht am: 08.02.2018 12:31
Rubrik: Gesundheit & Medizin


(Presseportal openBroadcast) - Global Neuroendocrine Tumours Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Pressekontakt:


Neuroendocrine tumours (NET) are the abnormal growths which begin in neuroendocrine cells. Neuroendocrine which are similar to the nerve cells and hormones producing cells. Neuroendocrine tumours are rare and can occur anywhere in the body. Most neuroendocrine tumours occur in the small intestine, lungs, rectum, appendix, and pancreas. Neuroendocrine tumours can be noncancerous (benign) or cancerous (malignant). NETs will arises from several neuroendocrine cells whose normal functions are to serve at neuroendocrine interface. Neuroendocrine cells will present throughout the body where hormones are produced but not only in the endocrine glands.

Neuroendocrine tumours therapeutics market expected to grow owing to increase in initiatives taken by various international organizations like American Association for Cancer Research and World Health Organization to treat neuroendocrine tumours are expected to drive the growth of the market. AACR provided $250,000 fund for the Prevention of neuro endocrine tumours. Rise in health care expenditure, increase in prevalence rate of neuroendocrine tumours in developing regions is anticipated to drive global neuroendocrine tumours market. Though the market is expected to witness healthy growth, lack of skilled healthcare professional and lower adoption of advanced treatment technologies in the developing economies are key restraints for neuroendocrine tumours market.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-neuroendocrine-tumours-therapeutics-market/#ulp-4H8Z4LpNMLEuOnnx


The global neuroendocrine tumours therapeutics market is segmented on the basis of the indication, distribution channel, drug class, and geographical regions.

Based on indication, global neuroendocrine tumours therapeutics market is segmented as
• Lung NET
• Others NET
• Gastrointestinal NET
• Pancreatic NET

Based on distribution channel, global neuroendocrine tumour treatment market is segmented as:
• Hospital Pharmacies
• Retail Pharmacies
• Others

Based on therapy, global neuroendocrine tumour treatment Market is segmented as
• Surgery
• Chemotherapy
• Radiation Therapy

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-neuroendocrine-tumours-therapeutics-market/#ulp-c654SbFYO64MsOhu


The neuroendocrine tumour treatment market is expected to gain steady traction in the foreseeable future as there are many novel drugs are in pipeline. Increase in NET incidence and prevalence globally. As per the estimation of Canadian Cancer Society (CCS), about 315 individuals were diagnosed with endocrine cancers in 2012 in Canada and rate is raising with early stage diagnosis and migration. Moreover, rise in survival rate of neuroendocrine tumours by treating with various medications are expected to have a positive impact on neuroendocrine tumours market. According to the study published in the JAMA Oncology Journal (2017), the survival rate for all neuroendocrine tumour treatment have improved, especially for distant-stage gastrointestinal neuroendocrine tumour treatment and pancreatic neuroendocrine tumour treatment.


Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-neuroendocrine-tumours-therapeutics-market/#ulp-14mlyhjMGhVjZqa3


Based on the geographical regions, global neuroendocrine tumours market is segmented into five key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. According to Cancer.Net, approximately 8,000 people are identified with neuroendocrine cancer every year in the U.S. Several key players functioning in neuroendocrine tumours therapeutics market are based in the U.S. Hence, in North America became main market for product launch and research and development activities. Furthermore, entrenched infrastructure and favorable reimbursement scenario are the major factors accountable for the strengthening of North America’s neuroendocrine tumours therapeutics market. Europe is the second largest market for neuroendocrine tumours therapeutics, followed by Asia-Pacific. Increase in prevalence of neuroendocrine cancer in Asia-Pacific along with the refining economic scenario is expected to play an important role in driving the market growth in the region.

Some of the players operating in the global neuroendocrine tumours therapeutics market include Pfizer Inc., (U.S), Eli Lilly & Company (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd.(Switzerland), Ipsen (France), Amgen, Inc. (U.S.), Teva Pharmaceuticals, Ltd. (Israel), and Bristol-Myers Squibb (U.S.).

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-neuroendocrine-tumours-therapeutics-market/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,
152 – 160 City Road,
London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com


Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.